Tuesday, 27 February 2024

Special Session: IACR 60th Anniversary Special Symposium:
Team Science Approaches to Fast-Track Innovations to the Clinic (IACR Members and all registered EAI-2024 participants are invited to attend) – not eligible for CME

09:30 - 12:45  Liffey Ballroom, Level 1

09:30  Welcome by IACR President
Session Chair: Tracy Robson, Ireland

09:32  Introduction
Session Co-Chair: Risteard O’Laoide, Ireland

09:40  Advancing Precision Medicine through Collaborative Team Science: Highlights from NCI’s CPTAC & ICPC Initiatives (REMOTE PRESENTATION)
Panel: Henry Rodriguez, United States

09:55  Spatial single cell analysis of stage II and III colorectal cancer and patient outcomes: Experiences from US-Ireland-N. Ireland Tripartite Collaboration
Panel: Fiona Ginty, United States

10:10  Epidemiology and Genetics Consortia
Panel:Montserrat Garcia-Closas, United Kingdom

10:25  The Health Dividend of Peace: Enhancing cancer research and care on the island of Ireland through the Ireland-Northern Ireland-US NCI Cancer Consortium (REMOTE PRESENTATION)
Panel: Satish Gopal, United States

Moderator: Sudipto Das, Ireland
Moderator: Sharon Glynn, Ireland

11:00  Coffee/Lunch Break

11:25  All-Island Cancer Research Institute: Ireland, Northern Ireland and Wider European Collaboration
Panel: William Gallagher, Ireland

11:40  The Critical Importance of Research in Delivering 21st Century Cancer Care: Indicators from the Lancet Oncology European Groundshot Commission
Panel: Mark Lawler, United Kingdom

11:55  European Cancer Groundshot / US Cancer Moonshot (REMOTE PRESENTATION)
Panel: Catharine G. Young, United States

12:10  Case Examples of EU Consortia
Panel: Annette Byrne, Ireland
Panel Discussion 2: IRE:Europe: Global collaborations: William Gallagher, Mark Lawler, Catharine Young, Annette Byrne, Angela Clayton-Lea; Cancer Trials Ireland
Moderator: Emma Creagh, Ireland
Moderator: Colm Ryan, Ireland

12:25

12:00 – 13:30  Cashbar Lunch Service & Exhibition Opening  
Forum, Ground Floor

Opening Remarks & Opening Keynote Lecture
13:00 - 14:00  Liffey Ballroom, Level 1

Rene Bernards (Co-Chair EACR)
Christine M. Lovly (Co-Chair AACR)
Tracy Robson (Co-Chair IACR)

13:15  Overcoming the Undruggable Nature of The Most Common Human Oncogene K-Ras
Keynote Speaker: Kevan Shokat (USA)

Coffee Break / Exhibition / Poster Viewing  (not eligible for CME)
14:00 - 14:30  Exhibition & Poster Area (FORUM, Ground Floor)

NanoString Technologies sponsored Industry Session  (not eligible for CME)
14:30 - 15:00  Liffey Ballroom, Level 1

Exhibition / Poster Viewing  (not eligible for CME)
15:00 - 15:30  Exhibition & Poster Area & Spotlight Area (Forum, Ground Floor)
Session 1: Immunotherapy / Immuno-Oncology

15:30 - 17:20  Liffey Ballroom, Level 1

Session Chair: William Gallagher (Ireland)

15:30  'The EMBO Keynote Lecture': T cell Recognition of Human Cancer
Speaker: Ton Schumacher (Netherlands)

16:00  Harnessing the Power of the Immune System: Do Solid Tumors Respond Better to Immunotherapy in the Neoadjuvant Setting?
Speaker: Myriam Chalabi (Netherlands)

16:30  Toxicities of Immunotherapy: Mechanisms and Future Directions
Speaker: Jarushka Naidoo (Ireland)

17:00  Proffered Paper: NeuVac, a novel therapeutic mRNA cancer vaccine, stimulates a robust immune response in vivo
E. King, L. Bennie, J. Bojdo, H. McCarthy, O. Piskareva (Ireland)

17:10  Proffered Paper: Targeting a Treg-specific deubiquitinase module for antitumor immune therapy
D. Fang (United States)

Transition Break

17:20 – 17:35  Exhibition & Poster Area (FORUM, Ground Floor)

Session 2: Cell Based Therapies

17:35 – 18:55  Liffey Ballroom, Level 1

Session Chair: John B.A.G. Haanen (The Netherlands)

17:35  CAR T Cells for Solid Tumors (REMOTE PRESENTATION)
Speaker: Crystal L. Mackall (USA)

18:05  Claudin-6 CAR-T ± CarVac for the Treatment of Solid Cancers
Speaker: John B.A.G. Haanen (The Netherlands)

18:35  Proffered Paper: Targeting MYC with the Novel Molecular Glue, GT19630 for the Treatment of Breast Cancer

18:45  Proffered Paper: Survival mechanisms common to immunotherapy and drug tolerant persister tumor cells
M. Davern, L. Benscics, B. Chan, M. Yorsz, M. Olson, P. Lizotte, P. Bhola, M.V. Maus, D. Barbie, A. Letai (United States)

Welcome Reception, Exhibition & Poster Viewing

19:00 – 20:00  Exhibition & Poster Area (FORUM, Ground Floor)

-end day 1-
Wednesday, 28 February 2024

Meet the Expert – Interactive Session

08:00 – 08:30  Liffey Ballroom, Level 1

08:00  Rules for a Successful Scientific Career; My Own Journey of Cancer Drug Discovery from Lab to Clinical Trial
Speaker: Tracy Robson (Ireland)

Session 3: Drug Combinations

08:30 - 09:50  Liffey Ballroom, Level 1

Session Chair: Alex Eustace (Ireland)

08:30  A Key Role of PML Nuclear Bodies in AML Response to Therapies
Speaker: Hugues de Thé (France)

09:00  Proffered Paper: Targeting RANK pathway sensitizes Rb-proficient TNBC tumors to CDK4/6 inhibitors
S. Casimiro, I. Gomes, R. Nunes, C. Abreu, A. Mansinho, R. Sousa, L. Costa (Portugal)

09:10  Proffered Paper: High-content Drug Screen Identification of Albendazole as a Novel Compound With Efficacy in Paediatric Acute Myeloid Leukaemia in Vitro and in Vivo
S. Lynch, R. Wilson, T. Ni Chonghaile, A. Thompson, K. Mills, L. Ross, K. Matchett (United Kingdom)

09:20  Unexpected, but Highly Synergistic Drug Combinations for Cancer Therapy
Speaker: Rene Bernards (Netherlands)

Plenary Session: Keynote Lecture

09:50 - 10:35  Liffey Ballroom, Level 1

Session Chair: Rene Bernards, The Netherlands

09:50  From the Immune Contexture to Immunoscore: Basic to Clinic
Keynote Speaker: Jerome Galon (France)

Coffee Break / Poster Viewing / Exhibition / Industry Spotlight (not eligible for CME)

10:35 - 11:05  Exhibition & Poster Area & Spotlight Area (FORUM, Ground Floor)
Session 4: The Precancer Genome

11:05 – 12:45  Liffey Ballroom, Level 1

Session Chair: Phil H. Jones (United Kingdom)

11:05  Lessons on Carcinogenesis from the Normal Esophagus
Speaker: Phil H. Jones (United Kingdom)

11:35  Targeting Clonal Hematopoiesis: Precision Prevention of Hematologic Malignancies
Speaker: Kelly Bolton (United States)

12:05  Defective Hematopoiesis as a Preleukemia Condition
Speaker: Jean Soulier (France)

12:35  Proffered Paper: Immune Evasion in the Progression of Barrett’s Oesophagus to Oesophageal Adenocarcinoma: a population-based study

Lunch Break / Exhibition / Poster Viewing (not eligible for CME)

12:45 - 15:00  Exhibition & Poster Area (FORUM, Ground Floor)

Posters in the Spotlight 1 (not eligible for CME)

13:30 - 14:30  Spotlight Area (Forum)

During the Posters in the Spotlight session, selected poster presenters present their poster for a duration of 5 minutes. Following each presentation, the moderator of the session will facilitate a 5-minute Q&A period to encourage engaging discussions between the presenters and the audience.

Moderator: Aideen Ryan, Ireland

13:30  Interferon epsilon limits ovarian cancer metastasis via regulation of peritoneal immune cells
N. Campbell, J. Gearing, P. Hertzog (Australia)  P-094

13:40  Semaphorins and their role in melanoma: implication in tumor aggressive features
S. D'Aguanno, M. Brignone, P. Rizzato, F. Valenti, C. Cota, F. Paolini, C. Mandoj, T. Mancuso, A. Sacconi, I. Manni, E. Migliano, L. Tamagnone, D. Del Bufalo (Italy)  P-142

13:50  Global regulation of gene expression in T-cell acute lymphoblastic leukemia by Ikaros-regulated facultative heterochromatin
S. Dovat, D. Bogush, Y. Ding, B. He (United States)  P-072

14:00  PMR-116, a second generation RNA Polymerase I inhibitor
N. Hein, R. Ferreira, K. Panov, A. Huglo, R. Rebello, E. Kusnadi, D. Drygin, M. Haddach, L. Furic, R. Hannan (Australia)  P-213

14:10  A revised model for colorectal cancer progression and metastasis—hypotheses for “metastasome”-driven diagnosis and therapy
H. Allgayer, N. Patil, J.H. Leupold (Germany)  P-243

14:20  ATR Inhibitor Efficacy Depends on CD8+ T-Cell Recruitment and MHC class-I Upregulation via Intratumoral Sting Pathway Activation in Immunocompetent Models of Small Cell Lung Cancer
T. Sen (United States)  P-103

MGI Tech UK Industry sponsored Industry Session (not eligible for CME)

14:00 - 14:30  Liffey Ballroom, Level 1
Exhibition / Poster Viewing

14:30 - 15:00  Exhibition & Poster Area (FORUM, Ground Floor)

Plenary Session: Keynote Lecture

15:00 - 15:45  Liffey Ballroom, Level 1

Session Chair: Rene Bernards, The Netherlands

15:00  Neoadjuvant Immune Checkpoint Blockade: A Window of Opportunity to Advance Cancer Immunotherapy (REMOTE PRESENTATION)
Keynote Speaker: Suzanne Topalian (USA)

Session 5: Liquid Biopsies

15:45 - 16:25  Liffey Ballroom, Level 1

Session Chair: William Gallagher (Ireland)

15:45  Cancer Liquid Biopsies: Investigating the Sum of their Parts for Patients Benefit
Speaker: Lorraine O'Driscoll (Ireland)

16:15  Proffered Paper: Prognostic significance of circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) in high-grade serous ovarian cancer

Coffee Break / Exhibition / Poster Viewing (not eligible for CME)

16:25 - 17:40  Exhibition & Poster Area & Spotlight Area (FORUM, Ground Floor)

Poster Discussion Session & Defence - Odd Numbers (not eligible for CME)

16:30 - 17:00  Exhibition & Poster Area (FORUM, Ground Floor)

Poster Discussion Session & Defence - Even Numbers (not eligible for CME)

17:00 - 17:30  Exhibition & Poster Area (FORUM, Ground Floor)

Session 6: Novel Targets / Undruggable Targets
Session Chair: Marisol Soengas (Spain)

17:40  
**Digital Twins for Personalized Oncology**  
Speaker: Walter Kolch (Ireland)

18:10  
**Advances in the Development of a Clinically Viable MYC Inhibitor**  
Speaker: Laura Soucek (Spain)

18:40  
Proffered Paper: First-in-class TET2 activator as a new therapeutic strategy to fight cancer  
D. Aguilar-Recarte, I. Puig, O. Arqués, L. Cabellos, I. Chicote, I. Marcote, C. Díaz, H. G. Palmer (Spain)

18:50  
Proffered Paper: Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-drug Conjugate for Treatment of CLDN18.2 Positive Cancers  

Conference Dinner (pre-registration required)  
20:00 – 22:30

-end day 2-
Thursday, 29 February 2024

Meet the Expert - Interactive Session

08:00 - 08:30 Liffey Ballroom, Level 1
08:00  Exploiting the Concept of Synthetic Lethality for Cancer Therapy Through Loss of Function CRISPR Screens
       Speaker: Rene Bernards (Netherlands)

Session 7: Preclinical Models

08:30 - 09:40 Liffey Ballroom, Level 1

Session Chair: Niamh Lynam-Lennon (Ireland)

08:30  Improved Pre-clinical Models for Translational Cancer Research
       Speaker: Annette Byrne (Ireland)
09:00  Models Matter: Lessons from Mice with Human Breasts
       Speaker: Cathrin Brisken (Switzerland)
09:30  Proffered Paper: Multi-omic profiling of small cell lung cancer patient-derived xenograft models reveals subtype-specific pathway alterations and therapeutic targets
       T. Sen (United States)

Coffee Break / Poster Viewing (not eligible for CME)

09:40 - 10:10 Exhibition & Poster Area & Spotlight Area (FORUM, Ground Floor)

Session 8: Tumour Microenvironment

10:10 - 11:20 Liffey Ballroom, Level 1

Session Chair: Tracy Robson (Ireland)

10:10  Role of Stromal Heterogeneity and Spatial Distribution in Breast Cancer
       Speaker: Fatima Mehta-Grigoriou (France)
10:40  Exploring and Therapeutically Exploiting the Tumor Microenvironment
       Speaker: Johanna A Joyce (Switzerland)
11:10  Proffered Paper: Understanding the role of the metastatic niche in metastatic progression
       S. Lin, T. Carroll, B. Elshenawy, V. Bridgeman, I. Malanchi, S. De Val, F. Pezzella, A. H Banham, A. L Harris (United Kingdom)

Lunch Break / Exhibition / Poster Viewing (not eligible for CME)

11:20 - 13:30 Exhibition & Poster Area & Spotlight Area (FORUM, Ground Floor)
Exhibition / Poster Viewing *(not eligible for CME)*

12:30 - 13:30  
Exhibition & Poster Area & Spotlight Area  
(Forum, Ground Floor)

**Posters in the Spotlight 2 (not eligible for CME)**

12:30 - 13:30  
Spotlight Area (Forum)

During the Posters in the Spotlight session, selected poster presenters present their poster for a duration of 5 minutes. Following each presentation, the moderator of the session will facilitate a 5-minute Q&A period to encourage engaging discussions between the presenters and the audience.

Moderator: Denis M Collins, Ireland

12:30  
Ivabradine induces BRCAAness to enhance Olaparib sensitivity as a novel treatment strategy for non-BRCA mutated breast cancer  
U.S. Khoo, H. Tsoi, M.H. Leung, E.P.S. Man, C. Gong (China)  
P-019

12:40  
IRAK1: a new marker of chemo-immuno-resistance and a potential therapeutic target in Non-Small Cell Lung Cancer  
S. Diiovanni, S. Parab, G. Doronzo, J. Kopecka, L. Righi, F. Bussolino, S. Novello, G.V. Scaglioni, C. Riganti, I.C. Salaroglio (Italy)  
P-212

12:50  
Can metabolic reprogramming alter T cell ability to kill lung tumour cells?  
M. Downs, E. Montgomery, C. Brown, N. Lewis, A. Bell, A. Krishnamoorthy, R. Morelli, A. Young, B. Ingram, D. Small, E. Kerr (United Kingdom)  
P-160

13:00  
Longitudinal detection of circulating tumour cells in epithelial ovarian cancer  
P-115

13:10  
Genetic and High Throughput Drug Screening revealed new synthetic lethal interactions to Proteasome Inhibitors in Multiple Myeloma  
P-049

13:20  
Immunological changes in the tumor microenvironment induced by ORCA-010, an oncolytic adenovirus, in early-stage Prostate cancer: Interim results from a Phase II/IIA clinical trial  
T. Brachtlova, R. Nadafi, W. Dong, V. Van Beusechem (The Netherlands)  
P-101

Session 9: Epigenetics

13:30 - 14:40  
Liffey Ballroom, Level 1

**Session Chair: Hugues de The** *(France)*

13:30  
Mechanisms of Cell Plasticity in Breast Cancer  
Speaker: Celine Vallot (France)

14:00  
Understanding and Targeting Disease Mechanisms in Cancers with Perturbations of the Polycomb Epigenetic Regulators  
Speaker: Adrian Bracken (Ireland)

14:30  
Proffered Paper: Histone H2A ubiquitination in chromatin structure, transcription and cancer  
E. Doyle, M. Davies, N. Orfali, D. Pasini, E. Conway (Ireland)
Closing Keynote Lecture & IACR Award Lecture

14:40 - 16:15  Liffey Ballroom, Level 1

Tracy Robson (Co-Chair IACR)
Rene Bernards (Co-Chair EACR)

14:40  Harnessing Senescence Biology for Cancer Suppression
Keynote Speaker: Scott Lowe (USA)

15:25  IACR Outstanding award for contribution to Cancer Medicine and Research
Award Lecturer: John Crown (Ireland)

16:05  Farewell & EAI 2024 Highlights

-end day 3-